December 2018 - Takis coordinates the project REVER3MAB

Takis is coordinating the project REVER3MAB, in collaboration with Istituto Regina Elena IRCCS and IBI – Istituto Biochimico Lorenzini, for the development of an anticancer monoclonal antibody aimed at "reverting" resistance to conventional oncological therapies.

The acronym "REVER3MAB" identifies a monoclonal antibody, directed against the ErbB3 protein able to block the proliferation of tumor cells in vitro and in vivo, with potential use as a therapeutic agent in the clinic.
Goals of the project are the optimization of the drug for clinical experimentation, its production on industrial scale and the setting-up of widely applicable humanized tumor models, the ImmunoAvatars. Counting on our expertise, we really expect to make a difference in the lives of cancer patients.

4-5 December 2018, Takis and Evvivax at BioFIT, Lille, France

Dr. Luigi Aurisicchio, CEO/CSO at Takis and Evvivax flew to Lille to represent both the companies at BioFIT 2018. This is the place where academia-industry collaborations get started, an exceptional platform for tech transfer and partnership building.

Luigi Aurisicchio took part in a round-table discussing the translational potential of veterinary medicine to complement current human Immune-Oncology approaches in the next future.
“I was honoured to contribute to the discussion with Takis/Evvivax experience and biotech perspectives. The possibility to work both in the human and animal health space provides a truly unique position and allows to appreciate two different worlds which converge into the One health approach”, declared Luigi Aurisicchio.
We hope that common grounds in human and animal health could lead to more frequent and translationally relevant collaborations all over the world.

14-16 November 2018 – Takis attends NeoAg Summit, Boston

The NeoAg Summit is the annual industry focused meeting dedicated to advancing neoantigen based cancer vaccines and cell therapies. The meeting brings together research groups and companies from all over the world working on neo-antigens, with the aim of exchanging ideas and results to overcome current limitations and accelerate safe, effective and scalable neoantigen-based therapies.

There in Boston, we found an exceptional platform to discuss the promises and challenges of an ever-expanding field of research. This experience has strengthened our determination to pursue the aim of realizing individualised therapeutic vaccines targeting tumor neoantigens in patients. We bet on personalized medicine, as we aware of the enormous benefits that could bring to patients.

5-7 November - Takis is at BIO-Europe, Copenaghen, Denmark

Dr. Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, flew to Copenaghen to attend BIO-Europe, the Europe’s largest partnering conference for biotech and life science.

Over 4,000 industry attendees from over 60 countries, representing more than 2,100 companies for three days of high-level networking: we could not miss it!
“Experience at BIO-Europe has been very successful for Takis. We found new clients and potential partnership for our programs, in particular regarding cancer vaccines and antibody production. In addition, we found potential partners for our project on invasive aspergillosis. We are looking forward to starting the new collaborations very soon”, commented Luigi Aurisicchio.

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. ("Applied DNA" or the "Company") announced that LineaRx, Inc. ("LineaRx"), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the "Agreement") with Takis S.R.L. and Evvivax S.R.L. ("Takis/Evvivax"), biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

Continue reading

11-13 October 2018 – Takis presents at NIBIT (Italian Network for Cancer Biotherapy), Milan, Italy

In recent decades, there has been a growing development of biological, immunological and pharmacological therapy in the treatment of cancer. NIBIT is the most important network in Italy covering all aspects of Cancer Biotherapy.

This year, Takis presents data on its neo-antigen cancer vaccine delivered by DNA electro-gene-transfer (DNA-EGT). Neo-antigens arising from cancer somatic mutations are a promising source of immunogens for cancer immunotherapy. At the same time, we demonstrated that DNA-EGT is a safe methodology, resulting in greater DNA cell uptake, enhanced protein expression and concomitant increase in longer-term immune responses against the target antigen.
Biotherapy represents the future of cancer treatments and we are committed to implementing a number of innovative technologies to offer new perspectives to cancer patients.